Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 5—May 2021
Research

Prevalence and Clinical Profile of Severe Acute Respiratory Syndrome Coronavirus 2 Infection among Farmworkers, California, USA, June–November 2020

Joseph A. Lewnard1Comments to Author , Ana M. Mora1, Oguchi Nkwocha, Katherine Kogut, Stephen A. Rauch, Norma Morga, Samantha Hernandez, Marcus P. Wong, Karen Huen, Kristin Andrejko, Nicholas P. Jewell, Kimberly L. Parra, Nina Holland, Eva Harris, Maximiliano Cuevas, Brenda Eskenazi, and on behalf of the CHAMACOS-Project-19 Study Team2
Author affiliations: University of California, Berkeley, Berkeley, California, USA (J.A. Lewnard, A.M. Mora, K. Kogut, S.A. Rauch, S. Hernandez, M.P. Wong, K. Huen, K. Andrejko, N.P. Jewell, N. Holland, E. Harris, B. Eskenazi); Universidad Nacional, Heredia, Costa Rica (A.M. Mora); Clínica de Salud del Valle de Salinas, Salinas, California, USA (O. Nkwocha, N. Morga, M. Cuevas); London School of Hygiene and Tropical Medicine, London, UK (N.P. Jewell); University of Arizona, Tucson, Arizona, USA (K.L. Parra)

Main Article

Figure 5

Prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positivity by transcription-mediated amplification (TMA) and seropositivity over time, Monterey County, California, USA, July 16–November 30, 2020. A) SARS-CoV-2 TMA; B) SARS-CoV-2 IgG ELISA. Estimated prevalence of SARS-CoV-2 infection and seropositivity in a sample population reached by outreach testing, reweighted to correct for differences in the population seeking testing over the course of the study. Lines delineate 95% CI around mean estimates (circles); medians and 95% CIs appear along the baseline.

Figure 5. Prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positivity by transcription-mediated amplification (TMA) and seropositivity over time, Monterey County, California, USA, July 16–November 30, 2020. A) SARS-CoV-2 TMA; B) SARS-CoV-2 IgG ELISA. Estimated prevalence of SARS-CoV-2 infection and seropositivity in a sample population reached by outreach testing, reweighted to correct for differences in the population seeking testing over the course of the study. Lines delineate 95% CI around mean estimates (circles); medians and 95% CIs appear along the baseline.

Main Article

1These authors contributed equally to this article.

2Members of the CHAMACOS-Project-19 Study Team are listed at the end of this article.

Page created: February 27, 2021
Page updated: April 20, 2021
Page reviewed: April 20, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external